NASH - Nonalcoholic Steatohepatitis Clinical Trials

11 recruitingLast updated: June 20, 2026

There are 11 actively recruiting nash - nonalcoholic steatohepatitis clinical trials across 31 countries. Studies span Not Applicable, Phase 3, Phase 1, Phase 2. Top locations include Bern, Switzerland, Chandler, Arizona, United States, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


NASH - Nonalcoholic Steatohepatitis Trials at a Glance

11 actively recruiting trials for nash - nonalcoholic steatohepatitis are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Bern, Chandler, and Barcelona. Lead sponsors running nash - nonalcoholic steatohepatitis studies include Can-Fite BioPharma, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Akero Therapeutics, Inc.

Browse nash - nonalcoholic steatohepatitis trials by phase

Treatments under study

About NASH - Nonalcoholic Steatohepatitis Clinical Trials

Looking for clinical trials for NASH - Nonalcoholic Steatohepatitis? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NASH - Nonalcoholic Steatohepatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NASH - Nonalcoholic Steatohepatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled322 locationsNCT06528314
Recruiting
Not Applicable

Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis
University of Minnesota48 enrolled4 locationsNCT03587831
Recruiting
Not Applicable

Non-Invasive Quantification of Liver Health in NASH (N-QUAN)

NASH - Nonalcoholic Steatohepatitis
Perspectum225 enrolled7 locationsNCT04054310
Recruiting
Not Applicable

A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients

SurgeryObesityCirrhosis+1 more
University Hospital, Lille100 enrolled1 locationNCT03472157
Recruiting

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Obesity, MorbidNASH - Nonalcoholic SteatohepatitisChronic Inflammation
Mayo Clinic60 enrolled1 locationNCT04232566
Recruiting
Phase 1

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease(NAFLD)

NASH - Nonalcoholic SteatohepatitisNAFLD - Non-Alcoholic Fatty Liver Disease
Tasly Biopharmaceuticals Co., Ltd.32 enrolled5 locationsNCT07128797
Recruiting
Phase 3

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NASH - Nonalcoholic Steatohepatitis
Massachusetts General Hospital60 enrolled1 locationNCT04833140
Recruiting
Not Applicable

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

ExerciseNASHNASH - Nonalcoholic Steatohepatitis+1 more
Milton S. Hershey Medical Center20 enrolled1 locationNCT06195943
Recruiting
Phase 2

Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis
Can-Fite BioPharma114 enrolled24 locationsNCT04697810
Recruiting

The European NAFLD Registry

Hepatocellular CarcinomaObesityCardiovascular Diseases+9 more
Newcastle University10,000 enrolled37 locationsNCT04442334
Recruiting

PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies

Liver CancerObesityMetabolic Syndrome+6 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS5,000 enrolled1 locationNCT04371042